SWOG 1607 A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

December 10, 2018
https://clinicaltrials.gov/ct2/show/NCT02965716
Cancer - Melanoma
Principal Investigator: Ding Wang, MD
CANCER, MELANOMA, ADVANCED, REFRACTORY
In Progress